<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2472">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04713878</url>
  </required_header>
  <id_info>
    <org_study_id>2020.05.20</org_study_id>
    <nct_id>NCT04713878</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia</brief_title>
  <official_title>A 8-Week Trial of Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kanuni Sultan Suleyman Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kanuni Sultan Suleyman Training and Research Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Due to the cytokine storm that develops as a result of Coronavirus Disease 2019 (COVID-19)&#xD;
      infection, some patients hospitalization to intensive care cause of pneumonia, Acute&#xD;
      Respiratory Distress Syndrome (ARDS) and multiple organ failure. Mortality is higher in&#xD;
      treatment-resistant cases.&#xD;
&#xD;
      Purpose of this study:&#xD;
&#xD;
        1. Providing immune modulation by Stem Cell Transplantation and reducing the damage caused&#xD;
           by cytokine storm to tissues and organs,&#xD;
&#xD;
        2. Correcting immunosuppression and fight against COVID-19 virus by editing B and T cells,&#xD;
&#xD;
        3. It is to accelerate healing in organ damage by increasing growth factors through&#xD;
           mesenchymal stem cells.&#xD;
&#xD;
      Primary outcome: Improvement of clinical symptoms, reduction of cytokine storm Secondary&#xD;
      outcome: Recovery of patients; from mechanical ventilation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design and participants This study was a single-center open-label, randomized trial&#xD;
      conducted at an Education and Training Hospital, Istanbul from May to July, 2020, and it was&#xD;
      performed according to the Declaration of Helsinki and approved by the Ethics Committee and&#xD;
      health ministry (No:2020.05.20). Written informed consent was obtained from all patients or&#xD;
      their representatives when data were collected prospectively.&#xD;
&#xD;
      Age, gender, mortality status, APACHE II score, number of days in ICU, procalcitonin and&#xD;
      C-reactive protein values, leukocyte values, comorbid diseases, The cluster of&#xD;
      differentiations 4 and 8 (CD4 and CD8), interleukin -2, interleukin -6, Tumor necrosis&#xD;
      factor-alpha-beta levels will be recorded.&#xD;
&#xD;
      Clinical results, changes in inflammatory and immune function levels, and side effects will&#xD;
      be recorded. The patient's lung function and symptoms will be recorded after Mesenchymal Stem&#xD;
      Cell transplantation. After treatment, lymphocyte, C-reactive protein, Tumor Necrosis&#xD;
      alpha-beta levels , interleukin-6 levels will be recorded.&#xD;
&#xD;
      Patients were divided into 3 groups:&#xD;
&#xD;
        1. group: Intubated without comorbidity (n:7)&#xD;
&#xD;
        2. group: Intubated with comorbidity (n:7)&#xD;
&#xD;
        3. group: No intubated (n:7)&#xD;
&#xD;
      Dosage of Mesenchymal stem cells:&#xD;
&#xD;
        1. 1 million cell/kg iv--------------------------------------------------day 0&#xD;
&#xD;
        2. 1 million cell/kg iv -------------------------------------------------day 2&#xD;
&#xD;
        3. 1 million cell/kg iv -------------------------------------------------day 4&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 8, 2020</start_date>
  <completion_date type="Actual">July 15, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Coronavirus Disease 2019 (COVID-19) patients with pneumonia&#xD;
1.group: Intubated without comorbidity, 2.group: Intubated with comorbidity, 3.group: No intubated</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of clinical symptoms as respiratory distress or need for oxygen support</measure>
    <time_frame>3 months</time_frame>
    <description>Recovery of patient from mechanical and oxygen support</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of cytokine storm parameters</measure>
    <time_frame>3 months</time_frame>
    <description>respiratory rates &lt; 30 times /min</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of pulmonary functions</measure>
    <time_frame>3 months</time_frame>
    <description>Oxygen saturation &gt; 93% and pulmonary imaging of focus within 24-48 hours &gt; 50% progression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of clinical symptoms</measure>
    <time_frame>3 months</time_frame>
    <description>arterial pressure of oxygen/the fraction of inspired oxygen&gt;300mmHg</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Coronavirus Disease 2019 (COVID-19) Pneumonia</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intubated without comorbidity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intubated with comorbidity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No intubated</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mesenchymal stem cells</intervention_name>
    <description>Intravenous infusion of Mesenchymal stem cells</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  aged 18-90 male or female&#xD;
&#xD;
          -  laboratory approve of RT-PCR (real-time reverse transcription polymerase chain&#xD;
             reaction) with COVID-19 infection&#xD;
&#xD;
          -  pneumonia assessed by chest radiography or computed tomography&#xD;
&#xD;
          -  In accordance with any of the following: 1)Respiratory rate ≥ 30 times / min 2) oxygen&#xD;
             saturation ≤ 93% 3) arterial pressure of oxygen/the fraction of inspired oxygen≤&#xD;
             300mmHg, 4) pulmonary imaging of focus within 24-48 hours &gt; 50% progression&#xD;
&#xD;
          -  patients who remain unresponsive to medications administered according to Ministry of&#xD;
             health guidelines&#xD;
&#xD;
          -  Patients who receiving invasive or non-invasive mechanical ventilation therapy in&#xD;
             intensive care&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Any kind of cancer, severe liver disease&#xD;
&#xD;
          -  Failure to provide informed consent or comply with test requirements&#xD;
&#xD;
          -  Known allergy or hypersensitivity to MSCs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ebru Kaya, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kanuni Sultan Suleyman Education and Training Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gursel Turgut, Prof Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Genkord</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ali Kocatas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kanuni Sultan Suleyman Education and Training Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Health Sciences</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 9, 2021</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>January 16, 2021</last_update_submitted>
  <last_update_submitted_qc>January 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kanuni Sultan Suleyman Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Ayca Sultan Sahin</investigator_full_name>
    <investigator_title>Assoc Prof</investigator_title>
  </responsible_party>
  <keyword>Mesenchymal stem cells</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 4, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT04713878/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

